MICOT PHARMA-B (02335) jumped nearly 6% in the afternoon session, trading up 5.94% at HK$32.12 with turnover reaching HK$12.68 million at the time of writing.

On the news front, the company's self-developed innovative drug XTL6001 has been accepted for poster presentation at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week 2026) for its renal disease research. This marks the third time this year that XTL6001-related studies have been selected for prestigious international academic platforms, following two poster presentations at ADA 2026 and two oral presentations at EASD 2026, further solidifying the company's deep-rooted research focus in metabolic and renal disease areas.

Notably, the company recently announced that the Phase II clinical trial of its self-developed neuroprotective candidate drug MT200605 for injection, designed to treat acute ischemic stroke (AIS), has successfully achieved its primary endpoint. As a small-molecule drug selected for China's National Major Science and Technology Projects and granted FDA Orphan Drug Designation, MT200605 leverages its unique triple-pathway mechanism covering the entire disease course to directly address core pain points in domestic stroke treatment. The drug is expected to fill the clinical gap for neuroprotective agents and reshape the competitive landscape of cardiovascular and cerebrovascular innovative drugs.